vs
ICU MEDICAL INC（ICUI）与美泰（MAT）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是ICU MEDICAL INC的1.6倍（$862.2M vs $540.7M），美泰净利率更高（7.1% vs -2.9%，领先10.0%），美泰同比增速更快（4.3% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-88.1M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -10.6%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
ICUI vs MAT — 直观对比
营收规模更大
MAT
是对方的1.6倍
$540.7M
营收增速更快
MAT
高出18.5%
-14.1%
净利率更高
MAT
高出10.0%
-2.9%
自由现金流更多
ICUI
多$124.1M
$-88.1M
两年增速更快
ICUI
近两年复合增速
-10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $862.2M |
| 净利润 | $-15.7M | $61.0M |
| 毛利率 | 37.5% | 44.9% |
| 营业利润率 | 1.0% | — |
| 净利率 | -2.9% | 7.1% |
| 营收同比 | -14.1% | 4.3% |
| 净利润同比 | 34.0% | 251.4% |
| 每股收益（稀释后） | $-0.63 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIMAT
| Q1 26 | — | $862.2M | ||
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $537.0M | $1.7B | ||
| Q2 25 | $548.9M | $1.0B | ||
| Q1 25 | $604.7M | $826.6M | ||
| Q4 24 | $629.8M | $1.6B | ||
| Q3 24 | $589.1M | $1.8B | ||
| Q2 24 | $596.5M | $1.1B |
净利润ICUIMAT
| Q1 26 | — | $61.0M | ||
| Q4 25 | $-15.7M | $106.2M | ||
| Q3 25 | $-3.4M | $278.4M | ||
| Q2 25 | $35.3M | $53.4M | ||
| Q1 25 | $-15.5M | $-40.3M | ||
| Q4 24 | $-23.8M | $140.9M | ||
| Q3 24 | $-33.0M | $372.4M | ||
| Q2 24 | $-21.4M | $56.9M |
毛利率ICUIMAT
| Q1 26 | — | 44.9% | ||
| Q4 25 | 37.5% | 45.9% | ||
| Q3 25 | 37.4% | 50.0% | ||
| Q2 25 | 37.9% | 50.9% | ||
| Q1 25 | 34.7% | 49.4% | ||
| Q4 24 | 36.1% | 50.7% | ||
| Q3 24 | 34.8% | 53.1% | ||
| Q2 24 | 34.8% | 49.2% |
营业利润率ICUIMAT
| Q1 26 | — | — | ||
| Q4 25 | 1.0% | 8.0% | ||
| Q3 25 | 2.6% | 21.9% | ||
| Q2 25 | 1.9% | 7.7% | ||
| Q1 25 | 2.1% | -6.4% | ||
| Q4 24 | 6.0% | 9.6% | ||
| Q3 24 | 1.4% | 26.5% | ||
| Q2 24 | 1.3% | 7.7% |
净利率ICUIMAT
| Q1 26 | — | 7.1% | ||
| Q4 25 | -2.9% | 6.0% | ||
| Q3 25 | -0.6% | 16.0% | ||
| Q2 25 | 6.4% | 5.2% | ||
| Q1 25 | -2.6% | -4.9% | ||
| Q4 24 | -3.8% | 8.6% | ||
| Q3 24 | -5.6% | 20.2% | ||
| Q2 24 | -3.6% | 5.3% |
每股收益（稀释后）ICUIMAT
| Q1 26 | — | $0.20 | ||
| Q4 25 | $-0.63 | $0.32 | ||
| Q3 25 | $-0.14 | $0.88 | ||
| Q2 25 | $1.43 | $0.16 | ||
| Q1 25 | $-0.63 | $-0.12 | ||
| Q4 24 | $-0.97 | $0.40 | ||
| Q3 24 | $-1.35 | $1.09 | ||
| Q2 24 | $-0.88 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $866.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $2.1B | $2.1B |
| 总资产 | $4.1B | $6.3B |
| 负债/权益比越低杠杆越低 | — | 1.11× |
8季度趋势，按日历期对齐
现金及短期投资ICUIMAT
| Q1 26 | — | $866.0M | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $691.9M | ||
| Q2 25 | — | $870.5M | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $308.6M | $1.4B | ||
| Q3 24 | $312.5M | $723.5M | ||
| Q2 24 | $302.6M | $722.4M |
总债务ICUIMAT
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.3B |
股东权益ICUIMAT
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.1B | $2.2B | ||
| Q3 25 | $2.1B | $2.3B | ||
| Q2 25 | $2.1B | $2.2B | ||
| Q1 25 | $2.0B | $2.1B | ||
| Q4 24 | $2.0B | $2.3B | ||
| Q3 24 | $2.0B | $2.3B | ||
| Q2 24 | $2.0B | $2.0B |
总资产ICUIMAT
| Q1 26 | — | $6.3B | ||
| Q4 25 | $4.1B | $6.6B | ||
| Q3 25 | $4.1B | $6.6B | ||
| Q2 25 | $4.1B | $6.2B | ||
| Q1 25 | $4.2B | $6.2B | ||
| Q4 24 | $4.2B | $6.5B | ||
| Q3 24 | $4.3B | $6.5B | ||
| Q2 24 | $4.3B | $5.9B |
负债/权益比ICUIMAT
| Q1 26 | — | 1.11× | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.08× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.03× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $-88.1M |
| 自由现金流率自由现金流/营收 | 6.6% | -10.2% |
| 资本支出强度资本支出/营收 | 4.6% | 7.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIMAT
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | $796.6M | ||
| Q3 25 | $56.7M | $72.0M | ||
| Q2 25 | $11.2M | $-300.1M | ||
| Q1 25 | $51.3M | $24.8M | ||
| Q4 24 | $40.2M | $862.1M | ||
| Q3 24 | $36.1M | $155.8M | ||
| Q2 24 | $82.0M | $-252.9M |
自由现金流ICUIMAT
| Q1 26 | — | $-88.1M | ||
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — |
自由现金流率ICUIMAT
| Q1 26 | — | -10.2% | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — |
资本支出强度ICUIMAT
| Q1 26 | — | 7.6% | ||
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — |
现金转化率ICUIMAT
| Q1 26 | — | — | ||
| Q4 25 | — | 7.50× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | 0.32× | -5.62× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.12× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | -4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
MAT
暂无分部数据
